Group 1: Yingjie Electric - In 2024, Yingjie Electric's revenue is projected to be 1.78 billion yuan, a year-on-year increase of 0.59%, while net profit is expected to decline by 25.19% due to delays in revenue recognition in the photovoltaic industry, inventory write-downs, and increased expenses [1] - The company's cash flow from operating activities increased significantly to 601.77 million yuan, up by 46.20 million yuan year-on-year [1] - New orders decreased by approximately 40%, but the backlog remains over 2.7 billion yuan, with expectations for overseas photovoltaic orders to contribute to revenue recognition by 2025 [1] Group 2: Dingyang Technology - Dingyang Technology has established a comprehensive sales system in the global market, exporting to over 80 countries and regions [2] - The company has launched 10 new products in 2024 and 6 new products in 2025, focusing on high-end electronic testing and measurement instruments [2] - Dingyang aims to enhance its international brand influence and market share through a high-end development strategy and improved marketing channels [2] Group 3: Aibo Medical - Aibo Medical achieved total revenue of 1.41 billion yuan in 2024, a year-on-year increase of 48.24%, with net profit rising by 27.77% [3] - The company is experiencing significant growth in its Dragon Crystal® PR product line, although initial production quality and costs are challenges [3] - Aibo Medical's artificial lens business is expanding, with a notable increase in market share and a focus on high-end products to counteract price drops due to industry policies [3] Group 4: Libang Instruments - In Q1 2025, Libang Instruments reported revenue of 420 million yuan, a decline of 5%, with domestic sales down by 20% but international sales up by 7% [4] - The company is optimistic about domestic sales recovery due to improved market conditions and is leveraging AI technology in ultrasound imaging and smart healthcare [4] - Libang's gross margin is expected to rise to 57.92% in 2024, driven by increased sales of high-margin products [4]

证券代码：300206 证券简称：理邦仪器 编号：2025-001 深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 ■业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | | 东吴证券、西南证券、太平洋证券、天风证券、国盛证券、中金资管、领颐资产、 华夏基金、明汯投资、广发基金、博远基金、蜂巢基金、益和源投资、创金合信、 | | 参与单位 | 中信期货、汇丰晋信基金、上海证券资管、易鑫安、上海天猊投资、颐和久富、 | | 名称及人 | | | 员姓名 | 深圳市正德泰投资、安信基金、华安基金、上海尚雅投资、申万菱信、前海天成 | | | 时代、中融基金、华杉投资、鑫诺嘉誉投资、大家资产管理、北京金百镕投资、 | | | 锦洋资产、西部证券、广东泓骐基金、国金证券 | | 时间 | 2025 年 4 月 24 日 15:00-16:00 | | 地点 | 公司董事会议室 | | 上市公司 | 董事长：张浩 | | 接待人员 | 董事会秘书：祖幼冬 | | 姓 ...